Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fenipentol→

Fenipentol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
583-03-9
Molecular formula
C11H16O
Molecular weight
164.24 g/mol
Drug class
Choleretic and cholagoguebenzyl alcohol derivative
Mechanism of action
Stimulates bile secretion and exocrine pancreatic secretion. It is classified in NLM MeSH as a cholagogue/choleretic; its detailed molecular mechanism is not fully established.
Indications / reported uses
  • Used as a choleretic or bile-flow-promoting agent in selected gastrointestinal and biliary preparations where fenipentol is authorised; product-specific indication and availability vary by jurisdiction.

Sources: https://www.ncbi.nlm.nih.gov/mesh/67013992 · https://meshb.nlm.nih.gov/record/ui?dcmsLinks=true&ui=C013992 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fenipentol Environmental Risk Assessment (ERA) (the Fenipentol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.